The role of immune cells in the liver tumor microenvironment: an involvement of gut microbiota-derived factors. (2nd June 2022)

• Record Type: Journal Article
• Authors: Kamiya, Tomonori; Ohtani, Naoko
• Is Part Of: International immunology. Volume 34:Number 9(2022)
• Page Start: 467
• Page End: 474
• Publication Date: 2022-06-02
• Subjects: deoxycholic acid (DCA) -- immune checkpoint inhibitor therapy -- lipoteichoic acid (LTA) -- senescence-associated secretory phenotype (SASP); Immunology -- Periodicals; 616.079
• DOI: 10.1093/intimm/dxac020
• Languages: English
• ISSNs: 0953-8178

Abstract

Abstract: Abstract More than 500 species of microbiota reside in the human intestine and coexist with humans, their host. Gut microbial metabolites and components are absorbed from the intestine and influence cells in the liver, including hepatocytes and stromal cells, such as liver sinusoidal endothelial cells, hepatic stellate cells, Kupffer cells, natural killer (NK) cells, NK T cells and other immune cells. This gut-originated axis to the liver is called the "gut–liver axis", which underscores the importance of the link between the gut and the liver. In this review, we discuss the gut microbial components and metabolites that affect cells in the liver, particularly in association with immune cells, and the related responses. We also highlight the mechanisms underlying gut microbiota-mediated liver carcinogenesis and discuss cancer prevention, including the recently clarified modulation of immune checkpoint inhibitor efficacy by the gut microbiota. Graphical Abstract: